Group 3

Notice convening the Annual General Meeting of AB Electrolux

Retrieved on: 
Friday, February 16, 2024

The Board of Directors proposes that the following guidelines for remuneration shall be approved by the Annual General Meeting of the Company.

Key Points: 
  • The Board of Directors proposes that the following guidelines for remuneration shall be approved by the Annual General Meeting of the Company.
  • The principles shall be applied to employment and consultancy agreements entered into after the 2024 Annual General Meeting, and to changes made to existing agreements thereafter.
  • The proposal to the 2024 Annual General Meeting for resolution on guidelines for remuneration corresponds, in all material aspects, with the guidelines adopted by the 2020 Annual General Meeting.
  • The resolution of the Annual General Meeting to implement the Share Program 2024 according to a) above requires that more than half of the votes cast at the Annual General Meeting are in favor of the proposal.

Notice convening the Annual General Meeting of AB Electrolux

Retrieved on: 
Friday, February 16, 2024

The Board of Directors proposes that the following guidelines for remuneration shall be approved by the Annual General Meeting of the Company.

Key Points: 
  • The Board of Directors proposes that the following guidelines for remuneration shall be approved by the Annual General Meeting of the Company.
  • The principles shall be applied to employment and consultancy agreements entered into after the 2024 Annual General Meeting, and to changes made to existing agreements thereafter.
  • The proposal to the 2024 Annual General Meeting for resolution on guidelines for remuneration corresponds, in all material aspects, with the guidelines adopted by the 2020 Annual General Meeting.
  • The resolution of the Annual General Meeting to implement the Share Program 2024 according to a) above requires that more than half of the votes cast at the Annual General Meeting are in favor of the proposal.

FDA Approves First Medication to Treat Severe Frostbite

Retrieved on: 
Wednesday, February 14, 2024

SILVER SPRING, Md., Feb. 14, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Aurlumyn (iloprost) injection to treat severe frostbite in adults to reduce the risk of finger or toe amputation.

Key Points: 
  • SILVER SPRING, Md., Feb. 14, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Aurlumyn (iloprost) injection to treat severe frostbite in adults to reduce the risk of finger or toe amputation.
  • Frostbite can occur in several stages, ranging from mild frostbite that does not require medical intervention and does not cause permanent skin damage, to severe frostbite when both the skin and underlying tissue are frozen and blood flow is stopped, sometimes requiring amputation.
  • Iloprost's efficacy in treating severe frostbite was primarily established in an open-label, controlled trial that randomized 47 adults with severe frostbite, who all received aspirin by vein and standard of care, into one of three treatment groups.
  • The two other groups received other medications that are unapproved for frostbite, given with iloprost (Group 2) or without iloprost (Group 3).

Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD

Retrieved on: 
Thursday, November 9, 2023

Alongside this, a late-breaking poster presentation with interim data from patients with chronic hepatitis B (CHB) from the Phase 2a AB-729-202 trial combining Arbutus Biopharma Corporation’s (NASDAQ: ABUS) RNAi therapeutic candidate, imdusiran (AB-729), with Barinthus Bio’s T cell stimulating immunotherapeutic candidate, VTP-300, and SoC NUC therapy.

Key Points: 
  • Alongside this, a late-breaking poster presentation with interim data from patients with chronic hepatitis B (CHB) from the Phase 2a AB-729-202 trial combining Arbutus Biopharma Corporation’s (NASDAQ: ABUS) RNAi therapeutic candidate, imdusiran (AB-729), with Barinthus Bio’s T cell stimulating immunotherapeutic candidate, VTP-300, and SoC NUC therapy.
  • Barinthus Bio is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer.
  • Preliminary immunology data suggests HBV-specific T cell IFN-γ production was enhanced in patients receiving imdusiran plus VTP-300 compared to placebo.
  • Dr. Karen Sims, Chief Medical Officer of Arbutus Biopharma, commented, “Imdusiran consistently delivers compelling efficacy and safety data in multiple Phase 2a populations and combinations.

CVR Energy Reports Second Quarter 2023 Results, Announces a Cash Dividend of 50 cents and a Special Dividend of $1.00

Retrieved on: 
Monday, July 31, 2023

Second quarter 2023 EBITDA was $300 million, compared to second quarter 2022 EBITDA of $401 million.

Key Points: 
  • Second quarter 2023 EBITDA was $300 million, compared to second quarter 2022 EBITDA of $401 million.
  • Adjusted EBITDA for the second quarter of 2023 was $347 million, down from $511 million in the second quarter of 2022.
  • “CVR Energy posted solid results for the second quarter of 2023 driven by strong crack spreads,” said Dave Lamp, CVR Energy’s Chief Executive Officer.
  • CVR Energy announced a second quarter 2023 cash dividend of 50 cents per share.

Colorado Energy & Carbon Management Commission Unanimously Approves Bayswater Onyx OGDP

Retrieved on: 
Friday, July 14, 2023

DENVER, July 14, 2023 /PRNewswire/ -- Bayswater Exploration & Production (Bayswater) is pleased to announce the unanimous approval of its Onyx Oil and Gas Development Plan (OGDP) by the newly-renamed Colorado Energy & Carbon Management Commission (formerly known as the Colorado Oil and Gas Conservation Commission or COGCC).

Key Points: 
  • DENVER, July 14, 2023 /PRNewswire/ -- Bayswater Exploration & Production (Bayswater) is pleased to announce the unanimous approval of its Onyx Oil and Gas Development Plan (OGDP) by the newly-renamed Colorado Energy & Carbon Management Commission (formerly known as the Colorado Oil and Gas Conservation Commission or COGCC).
  • The new Onyx horizontal development will utilize surface equipment currently located nearby on Bayswater's existing Leffler 26-A Pad Oil and Gas Location.
  • This is Bayswater's fourth OGDP application approved by the Commission since Colorado's new regulatory framework was implemented, and the first approval this year.
  • These four approved Bayswater permits encompass a total of 91 planned horizontal wells in the Denver Julesberg (DJ) Basin.

NZ workers have unacceptably high exposures to carcinogens – they need better protection and long-term health monitoring

Retrieved on: 
Thursday, June 29, 2023

The New Zealand Carcinogens Survey (NZCS), commissioned by WorkSafe New Zealand, was the first to examine the prevalence of occupational carcinogens in the working population.

Key Points: 
  • The New Zealand Carcinogens Survey (NZCS), commissioned by WorkSafe New Zealand, was the first to examine the prevalence of occupational carcinogens in the working population.
  • Workers in primary industries are exposed to the highest number of carcinogens at any level.
  • Māori and Pacific workers and men are the most likely to be exposed to at least one carcinogen.

Work-related exposures


    Work-related disease is estimated to account for 750-900 deaths a year in New Zealand. Cancer contributes to about half of these deaths and at least a third of work-related hospitalisations. These figures are largely based on overseas estimates applied to Aotearoa New Zealand health data. Establishing the number of workplace injuries is relatively straightforward but investigation of work-related cancers is much more difficult because:
    Therefore, understanding the prevalence, frequency and distribution of exposure to work-related carcinogens is crucial.

    Read more:
    Nail salon workers suffer chemical exposures that can be like working at a garage or a refinery

Which exposures matter?


    How do we know which workplace exposures contribute to cancer risk? The International Agency for Research on Cancer (IARC) regularly undertakes expert reviews of the relevant scientific literature to identify cancer-causing substances and practices. They classify exposures on the basis of the quality of evidence as:
    • Until the NZCS report, New Zealand-specific data on work exposures to carcinogens have been lacking.
    • It used a web-based exposure-assessment programme to estimate the likelihood of exposures and probable level based on questions to workers about substances, jobs and specific tasks.

What is to be done?

    • However, it is important to concentrate on the unmistakable evidence that a large number of people are exposed to high levels of workplace carcinogens.
    • But data alone are not sufficient; they need to inform action.
    • There are too many examples of Aotearoa being slower than other countries to act when sufficient evidence exists.
    • New Zealand was the last country in the world to halt the production of the toxic dioxin-contaminated herbicide 2,4,5-T, in 1987.
    • A lack of dedicated health services for occupational health hampers progress in addressing work-related diseases in New Zealand.

Vaccitech to Present Positive Final Data at EASL Congress for Phase 1b/2 HBV002 Study in Adults with Chronic Hepatitis B

Retrieved on: 
Wednesday, June 21, 2023

HBV002 (NCT04778904) is a Phase 1b/2a clinical trial of VTP-300 in adults with chronic Hepatitis B (CHB).

Key Points: 
  • HBV002 (NCT04778904) is a Phase 1b/2a clinical trial of VTP-300 in adults with chronic Hepatitis B (CHB).
  • “An effective immune response is likely to be essential to controlling chronic Hepatitis B,” said Meg Marshall, Vaccitech’s Chief Medical Officer.
  • VTP-300, encoding Hepatitis B virus (HBV) genotype C antigens, led to a decline in HBsAg in the majority of people infected with genotypes B and C viruses.
  • “Demonstrating cross-reactivity to genotypes B and C in participants, as well as to A-E in healthy subjects, is a promising step to being able to address chronic Hepatitis B infection in as many people as possible.”

Shield AI and Kratos Team up to Integrate AI Pilot on Valkyrie XQ-58

Retrieved on: 
Thursday, June 15, 2023

SAN DIEGO, June 15, 2023 /PRNewswire/ -- Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a Technology Company in the Defense, National Security and Global Markets, and Shield AI, Inc., a defense technology company building the world's best AI pilot, have signed an agreement to integrate and bring to market an AI pilot built by Shield AI for Kratos' XQ-58 Valkyrie, making real the concept of crewed-uncrewed teaming for jet aircraft.

Key Points: 
  • Integration of AI Pilot onboard XQ-58 Valkyrie will unlock concept of intelligent, affordable mass for US DoD and Allies – the Holy Grail of Deterrence
    SAN DIEGO, June 15, 2023 /PRNewswire/ -- Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a Technology Company in the Defense, National Security and Global Markets, and Shield AI, Inc., a defense technology company building the world's best AI pilot, have signed an agreement to integrate and bring to market an AI pilot built by Shield AI for Kratos' XQ-58 Valkyrie, making real the concept of crewed-uncrewed teaming for jet aircraft.
  • When you take an incredible, affordable uncrewed jet aircraft like the XQ-58 and pair it up with our AI pilot, you create a game-changing strategic deterrent."
  • "The Valkyrie is one of a very few number of uncrewed jet aircraft that are flying today, ramping in production, and are ready for AI pilot integration.
  • Shield AI has developed a combat-deployed AI pilot that has flown on a variety of platforms, including a quadcopter, their own manufactured Group 3 unmanned aircraft system called the V-BAT, and a modified F-16 fighter jet.

RapidFlight Introduces M2: A High Endurance, Fixed Wing Unmanned Aircraft System

Retrieved on: 
Monday, May 8, 2023

MANASSAS, Va., May 8, 2023 /PRNewswire/ -- RapidFlight, a Virginia-based unmanned aircraft manufacturing company, is proud to announce the launch of their new UAS, the M2. This innovative UAS features a high efficiency, heavy fuel engine with high-capacity generators to power various sensor, communication, and mission system payloads. Runway independent, the M2 can operate anywhere in the world to support the warfighter or first responder at the point-of-need.

Key Points: 
  • MANASSAS, Va., May 8, 2023 /PRNewswire/ -- RapidFlight, a Virginia-based unmanned aircraft manufacturing company, is proud to announce the launch of their new UAS, the M2 .
  • This innovative UAS features a high efficiency, heavy fuel engine with high-capacity generators to power various sensor, communication, and mission system payloads.
  • "With this flight, we've shown it is possible to build high performance aircraft at low cost and in record time.
  • With industry-leading UAS fabrication time, RapidFlight can deliver capability to the field faster than ever with the M2 and future systems.